GW Pharmaceuticals PLC (NASDAQ:GWPH)‘s stock had its “buy” rating reiterated by stock analysts at Cantor Fitzgerald in a note issued to investors on Monday. They presently have a $208.00 price objective on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective indicates a potential upside of 81.23% from the company’s current price.

The analysts wrote, “Tonight (11/20), the American Epilepsy Society (AES) published the abstracts for the upcoming annual meeting in early December.””

GWPH has been the topic of a number of other reports. Goldman Sachs Group, Inc. (The) restated a “neutral” rating and issued a $124.00 price target on shares of GW Pharmaceuticals PLC in a report on Friday, October 6th. Zacks Investment Research lowered GW Pharmaceuticals PLC from a “buy” rating to a “hold” rating in a report on Monday, July 24th. Maxim Group set a $135.00 price target on GW Pharmaceuticals PLC and gave the company a “buy” rating in a report on Monday, August 7th. Evercore ISI assumed coverage on GW Pharmaceuticals PLC in a report on Wednesday, August 16th. They issued an “outperform” rating and a $154.00 price target on the stock. Finally, Leerink Swann restated an “outperform” rating and issued a $153.00 price target (down from $160.00) on shares of GW Pharmaceuticals PLC in a report on Monday, October 2nd. One research analyst has rated the stock with a sell rating, four have issued a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. GW Pharmaceuticals PLC has a consensus rating of “Buy” and a consensus price target of $144.55.

Shares of GW Pharmaceuticals PLC (NASDAQ:GWPH) traded down $1.11 during trading on Monday, hitting $114.77. The stock had a trading volume of 414,820 shares, compared to its average volume of 319,576. GW Pharmaceuticals PLC has a 12 month low of $92.65 and a 12 month high of $136.95. The company has a debt-to-equity ratio of 0.02, a quick ratio of 10.26 and a current ratio of 10.39.

ILLEGAL ACTIVITY NOTICE: “GW Pharmaceuticals PLC (GWPH) Earns Buy Rating from Cantor Fitzgerald” was reported by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US & international copyright legislation. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/gw-pharmaceuticals-plc-gwph-earns-buy-rating-from-cantor-fitzgerald/1716657.html.

Several large investors have recently added to or reduced their stakes in GWPH. Janus Henderson Group PLC acquired a new stake in shares of GW Pharmaceuticals PLC in the second quarter valued at about $70,128,000. Pictet Asset Management Ltd. increased its position in shares of GW Pharmaceuticals PLC by 102.6% in the third quarter. Pictet Asset Management Ltd. now owns 355,263 shares of the biopharmaceutical company’s stock valued at $36,056,000 after acquiring an additional 179,911 shares during the last quarter. Redmile Group LLC increased its position in shares of GW Pharmaceuticals PLC by 33.8% in the second quarter. Redmile Group LLC now owns 444,936 shares of the biopharmaceutical company’s stock valued at $44,605,000 after acquiring an additional 112,392 shares during the last quarter. Employees Retirement System of Texas acquired a new position in GW Pharmaceuticals PLC during the second quarter worth approximately $5,313,000. Finally, Capital World Investors increased its position in GW Pharmaceuticals PLC by 6.3% during the second quarter. Capital World Investors now owns 675,800 shares of the biopharmaceutical company’s stock worth $67,749,000 after buying an additional 40,000 shares during the last quarter. 75.57% of the stock is currently owned by institutional investors and hedge funds.

GW Pharmaceuticals PLC Company Profile

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).

Analyst Recommendations for GW Pharmaceuticals PLC (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.